Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Junior explorer jumps on survey results

Sean Mason Sean Mason, Freelance
0 Comments| May 29, 2010

{{labelSign}}  Favorites
{{errorMessage}}

Stockhouse Canadian Small and Micro-cap Stock Report for Friday, May 28, 2010

TORONTO (SHfn) – Anglo Swiss Resources (TSX: V.ASW, Stock Forum) shares powered 19% to 28 cents on Friday after the micro cap explorer said it has completed an Aeroquest Aerotem III survey on its Nelson (gold/silver) Mining Camp project in British Columbia. A total of 1749 line km was flown and preliminary interpretation has three areas of high conductivity now referred to as the Silver Lynx, Gold Hill and Mammoth zones.

As well, shares of Theratechnologies (TSX: T.TH, Stock Forum) soared 67% to $4.85 as the biopharmaceutical company announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended by a 16 to 0 unanimous vote that tesamorelin, a growth hormone releasing factor, should be granted marketing approval by the FDA for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, based on a favorable benefit-risk profile. In 2008, Theratechnologies entered into a collaboration and licensing agreement with EMD Serono, Inc. for the exclusive commercialization rights to tesamorelin in the United States.

Zarlink Semiconductor (TSX: T.ZL, Stock Forum), meanwhile, reported that fourth-quarter revenue grew 8% to $58.5 million, compared with revenue of $54.4 million in the third quarter. This exceeded the company's guidance range of $56 million to $58 million. GAAP earnings per share for the quarter of five cents exceeded the company's guidance range of two cents to four cents per share excluding foreign exchange. Zarlink stock popped 13% to $1.77.

And, shares of Tekmira Pharmaceuticals (TSX: T.TKM, Stock Forum) added 10% at $1.27 on Friday after the provider of RNA interference (RNAi) therapeutics announced the publication of a series of studies demonstrating the ability of an RNAi therapeutic utilizing Tekmira's lipid nanoparticle technology, SNALP, to protect nonhuman primates from Ebola virus, a highly contagious and lethal human infectious disease.

Top Canadian Small/Micro-cap Advancers (as of 3 PM Eastern)
Top Canadian Small/Micro-cap Decliners

To read more articles by Sean Mason please click here



{{labelSign}}  Favorites
{{errorMessage}}